592 results on '"ONCOL 3: Translational research."'
Search Results
2. Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rg(null) Mice.
3. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.
4. FLT-PET imaging for early identification of antigen-specific immune responses in cancer patients.
5. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.
6. Targeting CD4(+) T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination.
7. Functional OCT4-specific CD4 and CD8 T cells in healthy controls and ovarian cancer patients.
8. Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination.
9. In vivo imaging of therapy-induced anti-cancer immune responses in humans.
10. The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients.
11. Abiraterone in metastatic prostate cancer without previous chemotherapy.
12. Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy.
13. Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients.
14. Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome.
15. Recovery of symptomatic extravasation of liposomal doxorubicin after dexrazoxane treatment.
16. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
17. Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.
18. DC-SCRIPT: AR and VDR regulator lost upon transformation of prostate epithelial cells.
19. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.
20. Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX.
21. Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs.
22. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
23. Renal cell carcinoma: a changing paradigm with a need for consensus.
24. Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
25. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
26. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells.
27. Inhibition of alpha-synuclein aggregation by small heat shock proteins.
28. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
29. Treatment nonadherence and long-term effects of narrowband UV-B therapy in patients with psoriasis.
30. The NDE1 gene is disrupted by the inv(16) in 90% of cases with CBFB-MYH11-positive acute myeloid leukemia.
31. Readily accessible bicyclononynes for bioorthogonal labeling and three-dimensional imaging of living cells.
32. Detecting only light chains, now what?.
33. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.
34. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.
35. A dynamic immunological synapse mediates homeostatic TCR-dependent and -independent signaling.
36. Lyophilisomes: Potential carriers for tumor targeting.
37. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).
38. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
39. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
40. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
41. Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking.
42. Functional differences between mesenchymal stem cell populations are reflected by their transcriptome.
43. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
44. Efficacy and outcome of autologous transplantation in rare myelomas.
45. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome.
46. Targeted therapy in metastatic colorectal cancer.
47. Gfi1 and Gfi1b: key regulators of hematopoiesis.
48. p27kip1 controls cell morphology and motility by regulating microtubule-dependent lipid raft recycling.
49. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice.
50. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.